Clinical trials: Tyrosine Kinase Inhibitor
Chronic Myeloid Leukemia, Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors.
Patients who suffer from chronic myeloid leukemia are treated by tyrosin kinase inhibitors (TKI) saying imatinib, nilotinib, dasatinib, bosutinib and ponatinib.
- Conditions
- Chronic Myeloid Leukemia, Tyrosine Kinase Inhibitor, Withdrawal Syndrome
- Trial name
- KIWIS (NCT03996096)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Caen
Tyrosine Kinase Inhibitor, Pharmacokinetics
Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitor in Patients With Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) consists of 3 clinical stages including chronic phase, accelerated phase and blast crisis. Patients may only survive for few more days to weeks once the disease progresses to blast crisis, even…
- Conditions
- Tyrosine Kinase Inhibitor, Pharmacokinetics, Therapeutic Drug Monitoring
- Trial name
- NCT05259228
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Lung Neoplasm, Carcinoma, Non-Small-Cell Lung
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
This is a Phase 1/2, open-label, first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of BLU-701 as monotherapy or in combination with either…
- Conditions
- Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms
- Trial name
- NCT05153408
- Testing
- BLU-701, osimertinib, carboplatin
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Blueprint Medicines Corporation
Thyroid Cancer, Tyrosine Kinase Inhibitor
HRQOL in Locally Advanced Thyroid Carcinoma
The purpose of this study was to explore the changes of health-related quality of life (HRQOL) in patients with locally advanced thyroid cancer (LATC) receiving TKI drugs (anlotinib, lenvatinib, etc.).
- Conditions
- Thyroid Cancer, Tyrosine Kinase Inhibitor, Health Related Quality of Life
- Trial name
- LATCQOL (NCT05824312)
- Testing
- Tyrosine kinase inhibitor drugs.
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fujian Cancer Hospital
Cancer, Cancer, Treatment-Related
Oncotool for Cancer Medications
The purpose of this study is to examine the efficacy of a psychosocial eHealth intervention on the proposed primary outcomes, TKI adherence and health related quality of life (HRQoL), in patients taking TKIs for cancer…
- Conditions
- Cancer, Cancer, Treatment-Related, Medication Adherence, Communication
- Trial name
- NCT03952312
- Testing
- Oncotool Intervention (symptom reporting + TKI education), Oncotool Control (health information)
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Northwestern University
Olverembatinib, Chronic Myeloid Leukemia, Chronic Phase
Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.
The purpose of this trial is to evaluate the efficacy and safety of olverembatinib(HQP1351) in patients with chronic myeloid leukemia in chronic phase (CML-CP) who are resistant and/or intolerant to at least two second-generation…
- Conditions
- Olverembatinib, Chronic Myeloid Leukemia, Chronic Phase, Tyrosine Kinase Inhibitors
- Trial name
- NCT05311943
- Testing
- olverembatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shenzhen Second People's Hospital
Non Small Cell Lung Cancer, Liquid Biopsy
ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)
The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for…
- Conditions
- Non Small Cell Lung Cancer, Liquid Biopsy, Tyrosine Kinase Inhibitor
- Trial name
- START-TKI (NCT05221372)
- Where
- Netherlands
- Volunteers
- 1,300 people
- Sponsor
- Erasmus Medical Center
Non-Small Cell Lung Cancer With EGFR T790M Mutation, With Brain and/or Leptomeningeal Metastasis
Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS
AZD9291 is an oral potent irreversible EGFR TKI selective for sensitizing EGFR mutation and T790M resistance mutation but sparing wild-type EGFR.
- Conditions
- Non-Small Cell Lung Cancer With EGFR T790M Mutation, With Brain and/or Leptomeningeal Metastasis, Failed Tyrosine Kinase Inhibitors
- Trial name
- NCT03257124
- Testing
- AZD9291
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Samsung Medical Center
The Optimal Sequence of Radiotherapy and Systematic Tyrosine Kinase Inhibitors in Treating Brain Metastases
Sequence of Radiation and Targeted Therapy in Brain Metastases
The investigators conducted a single institutional, retrospective cohort study to demonstrate the appropriate treatment strategy of upfront intracranial radiotherapy or upfront targeted therapy in patients with brain metastases…
- Trial name
- NCT04832672
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Chinese Academy of Medical Sciences
Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
This is the study to test combination regimen of Nilotinib and Ruxolitinib therapy for the treatment of patients with Philadelphia positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) who is resistant to…
- Conditions
- Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blastic Phase Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia
- Trial name
- NCT01914484
- Testing
- Nilotinib, Ruxolitinib
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- University Health Network, Toronto
Adenocarcinoma of Lung Stage IV, Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in, Somatic
Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center
The recent discovery of oncogenic drivers has revolutionized the management of advanced lung cancer by development of tyrosine kinase inhibitors targeted therapies.
- Trial name
- NCT04493827
- Where
- France
- Volunteers
- 114 people
- Sponsor
- Central Hospital, Nancy, France
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Tyrosine Kinase Inhibitor
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in early first complete remission improves the long-term outcomes for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
- Conditions
- Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Tyrosine Kinase Inhibitor, Minimal Residual Disease, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- NCT03624530
- Testing
- Tyrosine kinase inhibitor (TKIs)
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Nanfang Hospital, Southern Medical University
EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors
A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations
The main purpose of this study is to evaluate the safety and efficacy of Apatinib in combination with Gefitinib as compared to placebo in combination with Gefitinib in participants with stage ⅢB-IV Non-squamous non-small-cell…
- Trial name
- NCT02824458
- Testing
- Apatinib, Gefitinib
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)
RT Plus EGFR-TKI for Wild-type NSCLC
Concurrent chemoradiotheray is the standard care for patients with locally advanced non-small cell lung cancer (NSCLC), but often accompanying with high toxicity and poor tolerability.
- Trial name
- NCT02738983
- Testing
- Erlotinib (trade name: Tarceva®) or Icotinib (trade name: Conmana®), Radiotherapy
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Hangzhou Cancer Hospital